Related Experiment Video
Updated: Mar 2, 2026

Murine Kidney Transplant Technique
Published on: October 20, 2015
Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury
John C O'Horo1,2, Douglas R Osmon3, Omar M Abu Saleh3
1Division of Infectious Diseases, Rochester, Minnesota, USA ohoro.john@mayo.edu.
Abstract:
Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent non-contrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.
Insights
Coadministration of intravenous contrast medium and liposomal amphotericin B does not increase the risk of kidney injury in patients with fungal infections. This finding supports the safe use of both agents together when clinically necessary.
Area of Science:
- Nephrology
- Infectious Diseases
- Radiology
Background:
- Intravenous radiographic contrast medium and amphotericin B are frequently used in managing fungal infections.
- Both agents have been associated with potential nephrotoxicity via similar mechanisms.
- The safety of concurrent administration requires systematic investigation.
Purpose of the Study:
- To evaluate the renal safety of coadministering liposomal amphotericin B and intravenous contrast medium.
- To compare the incidence of renal injury in patients receiving both agents versus those receiving liposomal amphotericin B alone.
Main Methods:
- Systematic review of patients receiving coadministration of liposomal amphotericin B and intravenous contrast medium within 24 hours.
- Comparison with a control group of patients who received non-contrast medium studies.
- Propensity score adjustment for age, baseline kidney function, and other clinical factors.
Main Results:
- 114 cases and 85 controls were analyzed.
- No increased risk of renal injury was observed with the coadministration of contrast medium and liposomal amphotericin B.
- Propensity score adjustment did not alter the observed safety profile.
Conclusions:
- Coadministration of contrast medium and liposomal amphotericin B does not pose an excess risk of renal injury.
- This combination can be safely used when clinically indicated.
- The findings support current clinical practice for managing fungal infections requiring both interventions.
More Related Videos
10:55Fluorescence-quenching of a Liposomal-encapsulated Near-infrared Fluorophore as a Tool for In Vivo Optical Imaging
Published on: January 5, 2015
08:13In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Radiological Investigation I: X-ray and CT
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies VII: Vascular Imaging
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations